{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:04:42Z","timestamp":1789034682792,"version":"build-2803163510"},"reference-count":106,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Increased lipoprotein(a) (Lp(a)) levels are an independent predictor of coronary artery disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD and DAS. Lp(a) levels are genetically determinated in an autosomal dominant mode, with great intra- and inter-ethnic diversity. Most variations in Lp(a) levels arise from genetic variations of the gene that encodes the apolipoprotein(a) component of Lp(a), the LPA gene. LPA is located on the long arm of chromosome 6, within region 6q2.6\u20132.7. Lp(a) levels increase cardiovascular risk through several unrelated mechanisms. Lp(a) quantitatively carries all of the atherogenic risk of low-density lipoprotein cholesterol, although it is even more prone to oxidation and penetration through endothelia to promote the production of foam cells. The thrombogenic properties of Lp(a) result from the homology between apolipoprotein(a) and plasminogen, which compete for the same binding sites on endothelial cells to inhibit fibrinolysis and promote intravascular thrombosis. LPA has up to 70% homology with the human plasminogen gene. Oxidized phospholipids promote differentiation of pro-inflammatory macrophages that secrete pro-inflammatory cytokines (e.\u2009g., interleukin (IL)-1\u03b2, IL-6, IL-8, tumor necrosis factor-\u03b1). The aim of this review is to define which of these mechanisms of Lp(a) is predominant in different groups of patients.<\/jats:p>","DOI":"10.3390\/biom12010026","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T01:00:54Z","timestamp":1640566854000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Lipoprotein(a)\u2014The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-4781","authenticated-orcid":false,"given":"Sabina","family":"Ugov\u0161ek","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-3522","authenticated-orcid":false,"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pcad.2020.04.004","article-title":"What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?","volume":"63","author":"Cybulska","year":"2020","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00041433-199902000-00007","article-title":"Dietary and genetic interactions in the regulation of plasma lipoprotein(a)","volume":"10","author":"Loretto","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Schmitz","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: A mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein(a) in atherosclerosis: From pathophysiology to clinical relevance and treatment options","volume":"52","author":"Zavrtanik","year":"2020","journal-title":"Ann. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in Caucasian and Black individuals: The multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/CIRCULATIONAHA.110.006767","article-title":"Calcific aortic valve disease: Not simply a degenerative process","volume":"124","author":"Rajamannan","year":"2011","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein(a) as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jacc.2009.12.048","article-title":"The mysteries of lipoprotein(a) and cardiovascular disease revisited","volume":"55","author":"Kiechl","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00041433-199408000-00002","article-title":"Atherosclerosis and arterial influx of lipoproteins","volume":"5","author":"Nordestgaard","year":"1994","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"Unmet needs in understanding lipoprotein(a) pathophysiology: NHLBI working group recommendations to reduce risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"Physiol. Behav. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/CS20180306","article-title":"Atherosclerosis and inflammation: Overview and updates","volume":"132","author":"Geovanini","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/clc.4960270503","article-title":"Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis","volume":"27","author":"Deb","year":"2004","journal-title":"Clin. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.14712\/23362936.2019.9","article-title":"Lipoprotein(a)\u2014Link between atherogenesis and thrombosis","volume":"120","author":"Labudovic","year":"2019","journal-title":"Prague Med. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.V90.5.2027","article-title":"Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes","volume":"90","author":"Syrovets","year":"1997","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","article-title":"The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity","volume":"19","author":"Tsimikas","year":"2008","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_22","first-page":"412","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. The emerging risk factors collaboration","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.21037\/jtd.2017.01.40","article-title":"Lipoprotein(a) and inhibitors of proprotein convertase subtilisin\/kexin type 9","volume":"9","author":"Kotani","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein(a) as a risk factor for ischemic stroke: A meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): Prospective 15-year outcomes in the bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms","volume":"69","author":"Verbeek","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk insights from the FOURIER trial","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein(a) levels and restenosis after coronary stenting: Meta-analysis of nine cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_34","first-page":"1","article-title":"Recurrent coronary syndromes in a patient with isolated very-high lipoprotein(a) and the prothrombin genetic variant rs1799963 (G20210A): A case report","volume":"3","author":"Khantalin","year":"2019","journal-title":"Eur. Hear. J.-Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0002-9149(94)90279-8","article-title":"Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis","volume":"73","author":"Daida","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ozkan, U., Ozcelik, F., Yildiz, M., and Budak, M. (2019). Lipoprotein(a) gene polymorphism increases a risk factor for aortic valve calcification. J. Cardiovasc. Dev. Dis., 6.","DOI":"10.3390\/jcdd6030031"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis a prospective mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4250\/jcu.2015.23.2.59","article-title":"Aortic stenosis: Changing disease concepts","volume":"23","author":"Rashedi","year":"2015","journal-title":"J. Cardiovasc. Ultrasound."},{"key":"ref_40","first-page":"503","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"29","author":"Nanda","year":"2013","journal-title":"Cardiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.02.001","article-title":"Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity","volume":"119","author":"Pirro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","article-title":"New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease","volume":"27","author":"Tsimikas","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M036343","article-title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma","volume":"54","author":"Wiesner","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1106-4","article-title":"Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes","volume":"18","author":"Sabbah","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: A prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5455\/medarh.2015.69.232-235","article-title":"Correlation of inflammation and lipoprotein(a) with hypercoagulability in hemodialysis patients","volume":"69","author":"Haxhibeqiri","year":"2015","journal-title":"Med. Arch."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-004-0438-0","article-title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation","volume":"25","author":"Polat","year":"2005","journal-title":"Rheumatol. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cca.2007.12.015","article-title":"Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: Plasma concentrations and relationship to inflammation","volume":"390","author":"Wang","year":"2008","journal-title":"Clin. Chim. Acta."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: A study of 100 578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-2007-995851","article-title":"Atherosclerosis: Coagulation and fibrinolysis","volume":"24","author":"Sueishi","year":"1998","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/092986607782110202","article-title":"The molecular nature and consequences of lipoprotein(a)\u2019s association with platelets","volume":"14","author":"Barre","year":"2007","journal-title":"Protein Pept. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cardiores.2004.03.005","article-title":"Effect of lipoprotein(a) on platelet activation induced by platelet-activating factor: Role of apolipoprotein(a) and endogenous PAF-acetylhydrolase","volume":"63","author":"Tsironis","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/jcp.26050","article-title":"Lipoprotein(a): A missing culprit in the management of athero-thrombosis?","volume":"233","author":"Ferretti","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Thematic review series: Lipoprotein(a): Coming of age at last: Lipoprotein(a): Truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1538-7836.2005.01517.x","article-title":"Effects of high plasma lipoprotein(a) levels on tissue factor pathway inhibitor and the protein C pathway","volume":"3","author":"Meijers","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clinbiochem.2004.09.011","article-title":"The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease","volume":"38","author":"Bilgen","year":"2005","journal-title":"Clin. Biochem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-019-0803-9","article-title":"Looking at Lp(a) and related cardiovascular risk: From scientific evidence and clinical practice","volume":"21","author":"Stulnig","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tcm.2004.04.001","article-title":"The functions of plasminogen in cardiovascular disease","volume":"14","author":"Plow","year":"2004","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2014-03-560086","article-title":"Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels","volume":"124","author":"Ma","year":"2014","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1534\/g3.116.034702","article-title":"Effect of two lipoprotein(a)-associated genetic variants on plasminogen levels and fibrinolysis","volume":"6","author":"Wang","year":"2016","journal-title":"G3 Genes Genomes Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein(a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jth.13759","article-title":"Characterization of the I4399M variant of apolipoprotein(a): Implications for altered prothrombotic properties of lipoprotein(a)","volume":"15","author":"Scipione","year":"2017","journal-title":"J. Thromb. Haemostasis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HCO.0b013e32832ac21a","article-title":"Lipoprotein a: Where are we now?","volume":"24","author":"Tziomalos","year":"2009","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_72","first-page":"113","article-title":"Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia","volume":"113","author":"Keber","year":"2001","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/S0021-9258(18)52266-3","article-title":"Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: A potential mechanism in thrombogenesis","volume":"266","author":"Etingin","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00019501-200111000-00008","article-title":"Increased plasminogen activator inhibitor-1 and apolipoprotein(a) in coronary atherectomy specimens in acute coronary syndromes","volume":"12","author":"Shindo","year":"2001","journal-title":"Coron. Artery Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.99.19.2517","article-title":"Thrombogenic factors and recurrent coronary events","volume":"99","author":"Moss","year":"1999","journal-title":"Circulation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1161\/01.CIR.103.25.3062","article-title":"Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina","volume":"103","author":"Bogaty","year":"2001","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2008.04.020","article-title":"Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers","volume":"136","author":"Pineda","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.ATV.20.5.1354","article-title":"Influence of fibrin network conformation and fibrin diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy","volume":"20","author":"Collet","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V82.2.392.392","article-title":"Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?","volume":"82","author":"Hervio","year":"1993","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2741\/s107","article-title":"The physiopathology of lipoprotein(a)","volume":"S2","author":"Galvano","year":"2010","journal-title":"Front. Biosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a). Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1021\/bi962433d","article-title":"The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface","volume":"36","author":"Sangrar","year":"1997","journal-title":"Biochemistry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0021-9150(96)06030-3","article-title":"Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men","volume":"129","author":"Cremer","year":"1997","journal-title":"Atherosclerosis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0002-9343(00)00652-5","article-title":"Lipoprotein(a) as a predictor of myocardial infarction in middle-aged men","volume":"110","author":"Seed","year":"2001","journal-title":"Am. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.thromres.2006.06.013","article-title":"Association between inflammation, lipid and hemostatic factors in patients with stable angina","volume":"120","author":"Sagastagoitia","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0002-9149(99)00491-9","article-title":"Survey of C-reactive protein and cardiovascular risk factors in apparently healty men","volume":"84","author":"Rohde","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02546-y","article-title":"Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: A prospective, large cohort study","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1160\/TH02-10-0185","article-title":"Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease-13-year follow-up","volume":"90","author":"Niessner","year":"2003","journal-title":"Thromb. Haemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.ATV.18.8.1281","article-title":"Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty","volume":"18","author":"Alaigh","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/clc.21988","article-title":"Lipoprotein(a), interleukin-10, c-reactive protein, and 8-year outcome after percutaneous coronary intervention","volume":"35","author":"Kardys","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(02)02267-2","article-title":"The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting: The global evaluation of new events and restenosis after stent implantation study","volume":"40","author":"Zairis","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.thromres.2006.02.011","article-title":"Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction","volume":"119","author":"Speidl","year":"2007","journal-title":"Thromb. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/hrt.2005.061895","article-title":"PAI-1 and homocysteine, but not lipoprotein(a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting","volume":"92","author":"Marcucci","year":"2006","journal-title":"Heart"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"Mannsverk","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.hjr.0000116824.84388.a2","article-title":"Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction","volume":"11","author":"Thogersen","year":"2003","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijcard.2009.02.019","article-title":"The prognostic value of biomarkers after a premature myocardial infarction","volume":"143","author":"Pineda","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: Prespecified secondary end points in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: One-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"A13951","DOI":"10.1161\/circ.142.suppl_3.13951","article-title":"Abstract 13951: Safety, tolerability and efficacy of single-dose Amg 890, a novel siRNA targeting Lp(a), in healthy subjects and subjects with elevated Lp(a)","volume":"142","author":"Koren","year":"2020","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"154461","DOI":"10.1016\/j.metabol.2020.154461","article-title":"Advances in biological therapies for dyslipidemias and atherosclerosis","volume":"116","author":"Valanti","year":"2021","journal-title":"Metabolism"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/1\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:53:13Z","timestamp":1760169193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/1\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biom12010026"],"URL":"https:\/\/doi.org\/10.3390\/biom12010026","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]}}}